1. Home
  2. GVA vs ORKA Comparison

GVA vs ORKA Comparison

Compare GVA & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Granite Construction Incorporated

GVA

Granite Construction Incorporated

N/A

Current Price

$116.98

Market Cap

5.3B

Sector

Industrials

ML Signal

N/A

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

N/A

Current Price

$83.67

Market Cap

5.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GVA
ORKA
Founded
1922
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.6B
IPO Year
1995
1997

Fundamental Metrics

Financial Performance
Metric
GVA
ORKA
Price
$116.98
$83.67
Analyst Decision
Buy
Strong Buy
Analyst Count
5
13
Target Price
★ $171.67
$155.00
AVG Volume (30 Days)
410.1K
★ 795.9K
Earning Date
11-05-2026
11-11-2026
Dividend Yield
★ 0.45%
N/A
EPS Growth
★ 47.33
N/A
EPS
N/A
★ N/A
Revenue
★ $1,762,965,000.00
N/A
Revenue This Year
$22.01
N/A
Revenue Next Year
$9.42
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$97.26
$19.06
52 Week High
$162.08
$115.52

Technical Indicators

Market Signals
Indicator
GVA
ORKA
Relative Strength Index (RSI) 44.50 38.08
Support Level $114.55 $83.25
Resistance Level $129.07 $97.45
Average True Range (ATR) 3.08 4.39
MACD 0.44 -0.92
Stochastic Oscillator 54.74 20.05

Price Performance

Historical Comparison
GVA
ORKA

About GVA Granite Construction Incorporated

Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. The company focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, dams, tunnels, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, and rest from Materials segment.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Share on Social Networks: